It is thought that the beneficial effects with the use of tofacitinib for DM skin disease may be related to its inhibition of interferon signaling (by interfering with JAK 1/3), although, since JAK1 mediates signaling by both type I and II interferons, the relative role for each is unclear at present. Here, SGCG is linked to dermatomyositis.